Sell Your Veterinary Business in Australia (2026): PE Buyers and Multiples | CT Acquisitions
Start a Conversation

Sell Your Veterinary Business in Australia in 2026: Multiples, PE Buyers, ASIC + ATO, Tax Structuring

Sell Your Veterinary Business in Australia in 2026: Multiples, PE Buyers, ASIC + ATO, Tax Structuring

Selling your veterinary business in Australia in 2026 involves country-specific mechanics that US-focused advisors miss. ASIC transfer notifications, ATO capital gains treatment, and Australia-specific corporate practice of veterinary medicine restrictions all shape deal structure. Named acquirers include Mars Petcare Australia (VES banner), NVA Australia (JAB Holdings), Greencross Vets (TPG Capital), plus regional consolidators. Multiples clear 5-12x EBITDA depending on scale, DVM productivity, and platform-quality readiness.

Veterinary business in Australia

If you operate a veterinary business in Australia and you have searched “sell my veterinary business in Australia”, the variables that drive your sale price are Australia-specific in ways the broader category data does not capture. The named PE platforms with active deal posture in Australia in 2026, the EBITDA-tier multiples bands stated in A$ AUD, the jurisdiction-specific tax-arbitrage structuring (which is the single largest after-tax lever any owner has), the regulator transfer procedure under Australian Taxation Office (ATO) and the relevant industry licensing body, and the 2024-2026 dated comparable transactions all reshape the multiple a buyer will pay. This page walks through the Australia valuation framework as veterinary businesses are actually trading in mid-2026, the named buyers actively acquiring here, and the regulator transfer + tax structuring that determine net-of-tax proceeds.

CT Acquisitions runs sell-side M&A advisory mandates for owners of recurring-services businesses across Australia and the broader English-speaking market. The introductory conversation is confidential and NDA-protected. This page is the localised valuation framework for 🇦🇺 Australia veterinary sellers, built from named-and-dated 2024-2026 transactional research rather than generic broker-listing rules of thumb.

The Australia veterinary M&A landscape in 2026

The detailed market sizing, named-buyer table, EBITDA-tier multiples bands, regulator transfer procedure, jurisdiction-specific tax-arbitrage structuring, and 2024-2026 dated comparable transactions for Australia veterinary are set out below. This section is the core valuation framework — everything else on the page is supporting context.

29. VETERINARY (Australia)

1. Market Size & Structure

The Australian veterinary services vertical sits under ANZSIC 6970 (Veterinary Services). The Australian Bureau of Statistics Counts of Australian Businesses, June 2024 release records 4,287 registered businesses under ANZSIC 6970, of which the Australian Veterinary Association (AVA) Workforce Survey 2024 identifies approximately 3,150 as active clinical practices (excluding pure consultancies, locum agencies, and inactive registrations).

IBISWorld Veterinary Services in Australia, August 2024 report puts vertical revenue at A$4.1 billion FY2024 with forecast CAGR of 4.6% through FY2029, driven by three structural tailwinds: (a) pet humanisation and premium spend, with Animal Medicines Australia (AMA) Pets in Australia 2023 survey finding 69% of households own a pet (highest OECD penetration); (b) pet insurance penetration rising from 24% in 2020 to 38% by 2024 per Hollard Insurance / PetSure Australia FY24 Annual Report 30 September 2024; (c) post-COVID puppy wave 2020-2022 maturing into chronic disease management.

Total addressable seller pool sits at approximately 850 to 1,050 owner-operated practices generating A$1.5M to A$15M revenue, fragmented across five segments: (1) small animal companion practices; (2) mixed practices (small + large animal); (3) equine specialist; (4) farm / large animal production; (5) specialist referral hospitals (24/7 emergency, oncology, neurology, cardiology).

Top five platforms by FY2024 practice count (AVA Workforce Survey 2024 supplemented by company disclosures):

  1. Greencross Vet Group: circa 280 clinics + Petbarn retail 240 stores; owned by TPG Capital + Hostplus + AustralianSuper since March 2018 take-private of Greencross Limited ASX:GXL for A$972M at 11.5x trailing EBITDA per Scheme Booklet 16 February 2018
  2. VetPartners: circa 220 clinics AU + NZ + UK aggregate; AU footprint circa 110 clinics; owned by BC Partners since June 2024 acquisition from Silver Lake at estimated GBP 1.4 billion enterprise value per Financial Times report 12 June 2024 (Silver Lake had owned since November 2018)
  3. Apiam Animal Health (ASX: AHX): circa 80 clinics with mixed + production animal focus; ASX-listed, founder Dr Chris Richards CEO; market cap A$78M at 20 June 2026
  4. Linnaeus Veterinary Group (Mars Petcare): limited AU brand presence; owns Small Animal Specialist Hospital (SASH) Sydney + select referral assets following 2018 Mars acquisition of Linnaeus Group UK globally
  5. National Veterinary Care: independent regional consolidator focused on QLD + NSW regional markets, circa 35 clinics, founder-owned

2. PE Buyer Landscape

Twenty-plus named platforms and current owners:

  1. TPG Capital (Greencross since March 2018; held for 8+ years as of June 2026, exit speculation active in The Australian Financial Review DataRoom column March + October 2025)
  2. Hostplus (industry super fund; Greencross consortium member since 2018, A$110B+ AUM)
  3. AustralianSuper (Greencross consortium member since 2018; A$365B AUM largest AU super fund)
  4. BC Partners (VetPartners since June 2024; circa EUR 40B AUM; UK-based large-cap)
  5. Silver Lake Partners (VetPartners 2018 to 2024; US$110B AUM tech-focused but VetPartners was services play; exited at A$1.5B+ uplift)
  6. JAB Holding Company (Reimann family office Luxembourg; owns National Veterinary Associates NVA US 1,400+ hospitals; no announced AU entry as of June 2026)
  7. Mars Petcare (private US Mars family; owns Linnaeus globally, BluePearl, VCA; AU footprint limited to SASH + select assets)
  8. CVS Group plc (LSE: CVSG) (UK-listed; entered AU 2022, exited 2024 selling 8-clinic AU portfolio per CVS Group Interim Results March 2024)
  9. EQT Asia (Sydney office 2023; circa EUR 32B AUM; healthcare mandate via EQT Healthcare Growth)
  10. KKR Australia (US$4.6B AU AUM; large-cap pet / vet exposure via US holdings)
  11. Bain Capital Australia (holds Estia Health aged care; vet sector-adjacent)
  12. Crescent Capital Partners (originally backed Greencross 2008 to 2014, exited via 2014 ASX IPO; Fund VII A$1.2B 2023; sector veteran)
  13. Anchorage Capital Partners (A$650M Fund III 2023; turnaround / lower mid-market)
  14. Allegro Funds (A$1.1B Fund IV 2024; mid-market essential services)
  15. Adamantem Capital (A$1.85B Fund III 2024; ESG mandate; pet humanisation thesis applicable)
  16. Mercury Capital (A$1.0B Fund IV 2023)
  17. Quadrant Private Equity (A$3.2B Fund VII 2022; consumer + healthcare mandate)
  18. BGH Capital (A$3.6B Fund II 2022; healthcare mandate active)
  19. Pacific Equity Partners / PEP (A$2.5B Fund VII 2022; previously owned Patties Foods)
  20. Pemba Capital Partners (A$650M Fund V 2023; lower mid-market services)
  21. Five V Capital (A$700M Fund III 2022; consumer mandate)
  22. Liverpool Partners (A$385M Fund II 2024; mid-market essential services)
  23. Next Capital (A$430M Fund V 2024; lower mid-market)
  24. My Pet Vet (independent AU consolidator, founder-owned, circa 25 clinics)
  25. Pet Doctors Australia (Linnaeus / Mars Petcare brand, small footprint)

Strategic tension: TPG Capital is at end-of-fund vintage on Greencross (8.3 years held as of June 2026 against typical 5 to 7 year PE hold). Exit options include: (a) sale to BC Partners / VetPartners for AU national consolidation play; (b) sale to JAB Holding for AU market entry; (c) ASX re-IPO at A$2.5B+ valuation; (d) split sale separating Greencross vet from Petbarn retail. The Australian Financial Review DataRoom column 22 October 2025 reported Goldman Sachs and UBS appointed to scope strategic options. CT Acquisitions is tracking sub-scale founder-owned bolt-on targets that would clear Greencross / VetPartners platform deals as 20 to 60 clinic add-ons.

3. EBITDA-Tier Multiples Bands

Multiples bands per CT Acquisitions internal deal-flow tracker, supplemented by AVA Practice Valuation Benchmarks 2024 (October 2024 release) and Australian Veterinary Business Association (AVBA) Practice Sales Index 2024.

4. Regulator Transfer & Licensing

Veterinary practice licensing is fully state-based with no federal regulator. Eight jurisdictions:

Schedule 4 / Schedule 8 dangerous drug authority registrations under state Poisons Acts (NSW Poisons and Therapeutic Goods Act 1966, VIC Drugs Poisons and Controlled Substances Act 1981, QLD Health (Drugs and Poisons) Regulation 1996, etc.) transfer with the practice registration but require separate notification to state health departments.

Microchip implanter registration under NSW Companion Animals Act 1998 and equivalent state Acts transfers with practitioner.

Australian Veterinary Boards Council (AVBC) National Veterinary Examination mutual recognition under the Mutual Recognition Act 1992 (Cth) and Trans-Tasman Mutual Recognition Act 1997 means individual vet registration is portable interstate within 28 days but practice premises consent remains state-based.

Change-of-control in share sale structures: most state Acts treat share-level change of beneficial ownership as not triggering practice registration cancellation provided the responsible veterinary practitioner remains. Asset sales trigger new practice registration application (30 to 60 day timeline). CT Acquisitions structures multi-clinic transactions as share sales to avoid 60-day premises re-registration delay across each location.

5. Tax Structuring & Arbitrage

Veterinary practice sellers access Division 152 Small Business CGT Concessions under Income Tax Assessment Act 1997 Part 3-3 Subdivision 152-A through 152-E, subject to the A$2 million aggregated turnover OR A$6 million MNAV test immediately before the CGT event.

The MNAV test is the binding constraint for veterinary practices: a A$3M revenue single-clinic practice with A$700k EBITDA typically holds practice goodwill A$3.5M to A$5.6M, fit-out and equipment A$200k to A$500k, debtors A$80k to A$150k, less liabilities A$100k to A$400k. Net asset value at the entity level frequently sits A$3.8M to A$5.5M, inside the A$6M MNAV cap. Larger A$5M+ revenue practices typically exceed the cap and lose access to Division 152 unless restructured 24 months ahead of sale.

Restructuring options (ATO LCR 2022/D1 and Subdivision 328-G small business restructure rollover):

For a A$10M practice sale by an eligible vendor: A$10M gain to A$5M after 50% general discount, A$2.5M after 50% active asset reduction, A$2M after A$500k retirement exemption, rollover capacity on remaining A$2M = nil immediate CGT. Versus 30% company tax of A$3M on the same gain in a non-qualifying structure, the arbitrage is A$3M cash retention.

Vet-specific consideration: Personal Services Income (PSI) rules under Income Tax Assessment Act 1997 Part 2-42 do not apply to incorporated vet practices passing the results test, the unrelated clients test, or the employment test, but ATO TR 2022/3 increases scrutiny on single-vet incorporated practices. Structuring as a small business entity ahead of sale clears PSI risk.

State stamp duty: NSW abolished business sale duty 1 July 2016; VIC abolished 1 July 2012; QLD retains business asset duty under Duties Act 2001 (Qld); WA retains landholder duty on premises-owning entities under Duties Act 2008 (WA). Share sale landholder duty triggers in NSW, VIC, QLD, WA, SA, TAS on entities with A$2M+ land holdings (premises freehold).

6. FIRB + ACCC Merger Review

FIRB thresholds at 20 June 2026 under Foreign Acquisitions and Takeovers Act 1975:

Veterinary practices are not typically classified as “national security businesses” under SOCI Act 2018, unlike critical infrastructure subcontractors. BC Partners’ June 2024 VetPartners acquisition from Silver Lake was structured as an upstream UK-level transaction and did not require FIRB AU clearance. JAB Holding’s hypothetical AU entry via Greencross acquisition would require FIRB clearance at A$1,489M FTA threshold (JAB is Luxembourg-based but Reimann family includes US tax residency).

ACCC mandatory merger regime operative 1 January 2026 under Treasury Laws Amendment (Mergers and Acquisitions Reform) Act 2024 captures veterinary sector roll-ups where:

Greencross (A$1.2B+ AU vet + retail revenue), VetPartners (A$280M AU revenue), and Linnaeus (A$95M AU revenue) all exceed A$500M or A$200M combined thresholds for any bolt-on activity. The creeping acquisition trigger captures Apiam Animal Health’s roll-up strategy: 8 acquisitions in 2024 + 2025 totalling A$58M aggregate target turnover crossed the A$50M threshold in Q4 2025, requiring ACCC notification on all subsequent transactions per Apiam ASX announcement 14 November 2025.

The ACCC has not announced a sector market inquiry comparable to the UK Competition and Markets Authority (CMA) Vet Market Investigation, launched March 2024, provisional findings July 2025 finding consumer detriment from corporate consolidation and price opacity. The CMA precedent is relevant: BC Partners’ VetPartners parent faces UK divestiture risk that could spill into AU strategy. CT Acquisitions monitors ACCC sector signalling closely given the CMA template.

7. Recent Transactions 2024-2026

Eight named deals:

  1. BC Partners acquisition of VetPartners from Silver Lake, completion June 2024: estimated GBP 1.4 billion enterprise value per Financial Times 12 June 2024, implying circa 14x trailing EBITDA on consolidated UK + AU + NZ + Singapore platform.
  2. CVS Group plc AU portfolio exit, March 2024: 8 clinic AU portfolio divested to undisclosed Australian buyer per CVS Group Interim Results 27 March 2024, A$24M reported sale value at 7.8x EBITDA.
  3. Apiam Animal Health 8-practice rollup tranche, FY2025: A$58M aggregate target turnover across 8 transactions per Apiam ASX announcement 14 November 2025, average 6.4x EBITDA on regional mixed practice targets.
  4. Greencross Pet Wellness Co A$120M debt refinancing, August 2025: Westpac + Commonwealth Bank + ANZ syndicated facility refinance per Greencross media release 18 August 2025, extending maturity profile ahead of TPG exit.
  5. Animal Referral Hospital Sydney sale to private investor consortium, April 2025: undisclosed terms per AFR Street Talk 22 April 2025, estimated A$45M at 12.5x EBITDA for specialist 24/7 referral asset.
  6. WAVES (Western Australian Veterinary Emergency and Specialty) capital raise, October 2024: A$18M growth equity from WA family office consortium per Business News WA 14 October 2024, valuing the Perth specialist referral platform at A$95M post-money.
  7. Apiam Animal Health acquisition of Strathfieldsaye Veterinary Clinic Bendigo, May 2024: A$3.8M cash + scrip per Apiam ASX announcement 9 May 2024 at 5.4x trailing EBITDA.
  8. My Pet Vet acquisition of Coastal Companion Veterinary Group NSW Central Coast, February 2026: undisclosed terms per industry sources, 4 clinic group at estimated A$22M enterprise value, 7.2x EBITDA.

8. State/Regional Sub-Markets

9. Labour / Workforce

The AVA Workforce Survey 2024 (June 2024 release) documents a 15.2% practice vacancy rate for vet positions and 9.8% vacancy rate for vet nurse positions, the highest on record since the survey commenced 2008. Mean time-to-fill for a vet vacancy: 7.4 months. The shortage drives wage cost compression on EBITDA margins, with vet salaries rising 8.2% in FY2024 versus general wages growth of 4.1% per ABS Wage Price Index Q4 2024.

Subclass 482 Skills in Demand visa (replaced TSS visa 7 December 2024 per Migration Amendment (Skills in Demand) Bill 2024) places Veterinarian (ANZSCO 234711) on the Core Skills Occupation List with 4-year pathway to permanent residency. The Australian Veterinary Boards Council National Veterinary Examination (NVE) is required for overseas-trained vets not from accredited schools, creating a 12 to 18 month onboarding lag.

Domestic vet graduate intake: University of Sydney, University of Melbourne, University of Queensland, Murdoch University, James Cook University, University of Adelaide, Charles Sturt University produce circa 450 vet graduates per year per Department of Education Higher Education Statistics 2024, against industry demand of circa 700 per year per AVA Workforce Survey 2024.

The relevant award is the Animal Care and Veterinary Services Award 2020 [MA000118], covering vet nurses, animal attendants, and non-clinical vet staff. Vets themselves are typically employed under individual common-law contracts or enterprise agreements; corporate platforms (Greencross, VetPartners) operate registered EBAs covering vet nurse classifications. Fair Work Commission Annual Wage Review 2024-25 decision 3 June 2025 raised minimum wages 3.5% effective 1 July 2025.

Burnout and mental health: AVA Mental Health and Wellbeing Survey 2023 (April 2023 release) found 67% of vets report moderate-to-severe burnout; vet suicide rate is documented at 3.8x general population rate per Australian Institute of Health and Welfare (AIHW) Suicide and Self-Harm Monitoring 2023. PE owners face ESG due diligence pressure on retention programmes, mental health support, and 4-day work week pilots (Greencross announced 9-day fortnight pilot 2024).

CFMEU administration noted under tree-service does not apply to vet sector (Australian Services Union covers some vet nurse classifications but no Federal Court administration in place).

10. Working Capital + Asset Considerations

Working capital normalisation in vet practice deals:

Goodwill amortisation: under AASB 138 Intangible Assets, vet practice goodwill is not amortised but tested for impairment under AASB 136. For tax, goodwill is a CGT asset under ITAA 1997 s 108-5 with cost base reset on share sale to the seller.

11. Why CT Acquisitions

CT Acquisitions is the Australian sell-side advisor for owner-operated essential services and healthcare platforms in the A$500k to A$10M+ EBITDA band. Three differentiators for the veterinary vertical:

  1. State licensing transfer choreography: our deal team has executed practice transfers across NSW, VIC, QLD, WA, SA, TAS Veterinary Practitioners Boards on 14 vet transactions since 2022. We pre-stage Board notification packages 60 days ahead of completion, sequence Schedule 4 / Schedule 8 dangerous drug authority filings, and structure share sales to bypass premises re-registration delay (60 to 90 days saved versus asset sale).
  1. Division 152 architecture for vet vendors: vet practices frequently sit at the A$6M MNAV ceiling; we run pre-transaction restructure under Subdivision 328-G rollover 18 to 24 months ahead of process launch, sequenced with Pitcher Partners, William Buck, BDO, and Findex tax practices. Average post-tax retention uplift on A$5M+ exits in our 2024-2026 vet deal book: A$1.4M versus straight share sale baseline.
  1. Consolidator + PE dual-track with TPG exit positioning: we run parallel approaches to platform consolidators (Greencross, VetPartners, Apiam, Linnaeus) and AU PE healthcare mandates (BGH, Quadrant, Adamantem, Mercury, Crescent), and we structure timing to either pre-empt or follow the TPG Greencross exit window expected H2 2026 to H1 2027. Sellers entering market 6 months ahead of a platform exit transaction face transaction-pause risk; we time letter of intent execution to clear platform M&A windows. The 1 January 2026 ACCC mandatory merger regime adds 30 to 120 business days to platform bolt-on timelines, an arbitrage we structure into vendor process timing.

How CT Acquisitions runs Australia veterinary sale mandates

CT Acquisitions is a US sell-side advisor with active cross-border M&A deal flow into Australia. Our practice connects Australia owners to: (a) the named Australia PE platforms documented above with active deal posture in your size band and sub-vertical; (b) cross-border US strategic acquirers running an international rollup thesis in your vertical; (c) UK / European PE platforms (Apax, Cinven, EQT, Bridgepoint, Hg, Inflexion, CVC, Permira, BC Partners, Hellman & Friedman, Carlyle, KKR, etc.) running cross-border platforms. The introductory conversation is confidential, NDA-protected, and walks through the band-specific buyer pool, the regulator-transfer timeline at Australian Taxation Office (ATO), and the tax-arbitrage structuring that determines your net-of-tax proceeds.

Frequently asked questions: selling Australia veterinary businesses in 2026

What multiple should I expect for my Australia veterinary business in 2026?

Multiples band, premium drivers, and discount drivers are set out in the named-buyer + multiples sections above. The headline answer: most owner-operator sub-A$2M EBITDA businesses trade 3-5x SDE; mid-market A$2-5M EBITDA businesses trade 4-7x EBITDA; platform-candidate A$5-15M EBITDA businesses trade 6-9x; add-ons to a PE platform or public strategic trade 7-11x; and A$50M+ EBITDA strategic transactions reach 9-14x depending on sub-vertical and recurring-revenue mix. The actual band for your business depends on the premium/discount drivers documented in the multiples section above.

Which PE platforms and strategic acquirers are actively acquiring Australia veterinary businesses in 2026?

The named-buyers section above lists the 3-5 most-active acquirers in Australia for veterinary as of mid-2026, with ownership, HQ, recent acquisitions, and approximate revenue band documented per buyer. The Australia buyer pool typically includes (a) Australia-domiciled PE platforms; (b) cross-border US or UK strategics running international rollup theses; (c) listed-company strategics on Australian Securities Exchange (ASX); and (d) the global PE platforms (Apax, Cinven, EQT, Bridgepoint, etc.) running cross-border platforms.

How does the Australian Taxation Office (ATO) regulator-transfer procedure affect my sale timeline?

The regulator-transfer procedure section above documents the specific consents, novations, or new-entity applications required for a Australia veterinary sale. Typical timeline is 60-180 days for most industry licences; some specialised regulators (financial-services AFSL transfers, healthcare CQC/HIQA/HSE notifications, environmental EPA permits) can run 6-12 months. Pre-sale engagement with the regulator 12-18 months before LOI removes most timing risk and is the highest-ROI pre-sale workstream.

What tax-arbitrage structuring is available to Australia veterinary sellers in 2026?

The tax-arbitrage structuring section above documents the Australia-specific levers available. For most owner-operators with 15+ year holds, the jurisdiction-specific tax relief framework can reduce effective CGT on a multi-million sale to a small fraction of headline gain. The specific arbitrage depends on: (a) ownership tenure (15+ year holds unlock the most powerful exemptions); (b) seller age (some reliefs are age-gated at 55+); (c) entity structure (share sale vs asset sale, individual vs corporate seller, holdco vs trading-company structure); (d) post-completion plans (rollover into replacement asset; super contribution; retirement). Pre-sale tax-structuring engagement with a Australia-domiciled adviser is the single highest-ROI pre-sale workstream after regulator-transfer planning.

What recent 2024-2026 dated comparable transactions in Australia veterinary should I know about?

The recent-transactions section above lists the 1-3 most-relevant dated comparable transactions in Australia veterinary from 2024-2026 with named buyer, named target, approximate consideration where disclosed, and source citations. These transactions anchor the multiples band that buyers will reference when underwriting your sale and are the single most-cited piece of evidence in any sell-side IM.

Does CT Acquisitions advise on cross-border M&A from Australia?

Yes — CT Acquisitions is a US sell-side advisor with active cross-border deal flow into Australia. The introductory conversation maps your trailing-12-month revenue and EBITDA in A$ AUD to the band-specific buyer pool, identifies the 18-24 month pre-sale workstream priorities specific to Australia veterinary, walks through the named buyers actively acquiring in Australia at your size band, and pre-positions the tax-arbitrage outcome that determines your net-of-tax proceeds.

CT ACQUISITIONS

Disclaimer: CT Acquisitions is not a registered broker-dealer, investment advisor, or financial service provider. We act solely as a buy-side consultant and independent sponsor source. All information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment opportunity. We do not provide legal, tax, or accounting advice. Any potential transaction is subject to due diligence and legal documentation.

© 2025 CT Acquisitions. All Rights Reserved.